Global Therapeutics for Women’s Health Market to 2026 – Featuring Abbvie, Bayer and Eisai among Others – ResearchAndMarkets.com

January 17, 2022 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Therapeutics for Women’s Health: Technologies and Global Markets” report has been added to ResearchAndMarkets.com’s offering.

This report is an analytical business tool that comprehensively evaluates the global market for women’s health therapeutics. The format of the study is organized around the following topics –

  • Detailed study around women’s diseases, such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and PCOS.
  • Disease incidence and prevalence.
  • Regulatory structure of pharmaceutical industry.
  • Market characterization, unmet need, market size and segmentation.
  • Market drivers and restraints.
  • Detailed market projections through 2026.
  • Competition and market shares.
  • Pricing and reimbursement.
  • Marketed and pipeline (R&D) products along with description, regulatory status, and clinical trials.
  • Observations and conclusions regarding the future of market for women’s health therapeutics.
  • Profiles of market participants and associations.

Report Includes

  • 58 data tables and 56 additional tables
  • An overview of the global market and technologies for women’s health therapeutics
  • Estimation of the market size and analyses of global market trends, with data from 2018, 2019, 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
  • Detailed study around women’s diseases such as endometriosis, postmenopausal osteoporosis, menopause, breast cancer and polycystic ovary syndrome (PCOS); their historical background, stages, symptoms, risk factors and genetic factors, diagnosis, and treatment, etiology, pathophysiology, epidemiology, and economic burden
  • Discussion on aging and women’s health disorders, women & sexual health such as female sexual arousal disorder, female orgasmic disorder, and vaginismus and relation between infertility and cancer
  • Coverage of regulatory structure, pricing, and reimbursement scenarios; marketed and pipeline (R&D) products, and clinical trials
  • Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
  • Market share analysis of the key companies of the industry and coverage of their proprietary technologies, strategic alliances, and other key market strategies

Market Dynamics

Driving Factors

  • Aging Female Population
  • Government Involvement and Increased Funding
  • Increasing Awareness Regarding Women’s Disorders and Treatments

Restraints

  • Poor Diagnosis
  • Availability of Alternate Treatment Options and Lifestyle Changes
  • Unavailability of Novel Treatments
  • High Treatment Cost of Osteoporosis

Opportunities

  • Rising Female Population in Asia-Pacific
  • Increased Demand for Technology Innovation

Companies Mentioned

  • Abbvie Inc.
  • Amgen Inc.
  • Asahi Kasei
  • Astrazeneca plc
  • Bayer AG
  • Bristol-Myers Squibb
  • Daiichi Sankyo Co. Ltd.
  • Eisai
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Merck Kgaa
  • Novartis AG
  • Novo Nordisk
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/tn3lk8

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900